Corticosteroid-induced osteoporosis: Detection and management

Drug Safety

Volumn 24, Issue 8, 2001, Pages 607-624

  Adachi, J D ^a   Papaioannou, A ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; ESTROGEN; FLUORIDE; RALOXIFENE; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE DENSITY; CLINICAL FEATURE; HORMONE SUBSTITUTION; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW;

ADRENAL CORTEX HORMONES; APOPTOSIS; BONE DEVELOPMENT; BONE RESORPTION; CALCITONIN; CLINICAL TRIALS; DIPHOSPHONATES; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 0034939624     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124080-00005     Document Type: Review

References (168)

1. Glucocorticoid-induced osteoporosis: Pathogenesis and management
2. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computer tomography
3. Rheumatoid arthritis, corticosteroid therapy and hip fracture
4. Fractures after rheumatoid arthritis
5. Corticosteroid effects on proximal femur bone loss
6. Glucocorticoid-induced osteoporosis
7. Steroid-induced fractures and bone loss in patients with asthma
8. Epidemiology of osteoporosis
9. The basophil adenomas of the pituitary body and their clinical manifestations
10. New developments in the pathogenesis and treatment of steroid-induced osteoporosis
11. Prevention of corticosteroid-induced osteoporosis: Results of a patient survey
12. A UK consensus group on management of glucocorticoid-induced osteoporosis: An update
13. Management of corticosteroid-induced osteoporosis
14. Glucocorticoid-induced osteoporosis
15. Clinical utility of bone mass measurements in adults: Consensus of an international panel
16. Current and potential future drug treatment for osteoporosis
17. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
18. Glucocorticoid-induced osteoporosis: Pathogenesis, prevention and treatment
19. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: Bones of contention
20. Prevention and management of glucocorticoid-induced osteoporosis
21. Management of corticosteroid-induced osteoporosis
22. Corticosteroid osteoporosis
23. Corticosteroid-induced osteoporosis
24. Glucocorticoid-induced osteoporosis
25. Corticosteroid osteoporosis
26. Glucocorticoid-induced osteoporosis: Pathogenesis, prevention and treatment with special regard to the rheumatic diseases
27. Steroid and drug-induced osteoporosis
28. Corticosteroid-induced osteoporosis
29. Prevention and treatment of glucocorticoid-induced osteoporosis: A pathogenetic perspective
30. Corticosteroids and osteoporosis
31. Glucocorticoid-induced osteoporosis: Mechanisms for bone loss; evaluation of strategies for prevention
32. Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study
33. Corticosteroid induced osteoporosis: Follow-up over 3 years
34. Corticosteroid-induced bone loss: Prevention and management
35. A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists
36. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: Effect of low dose corticosteroids
37. Generalized bone loss in patients with early rheumatoid arthritis
38. Glucocorticoids and bone
39. Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass
40. Radiologic aspects of glucocorticoid-induced bone disease
41. Corticosteroid-induced bone loss in men
42. Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis
43. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis: A population based study
44. Use of oral corticosteroids and risk of fractures
45. Vertebral fracture risk with long-term corticosteroid therapy; prevalence and relation to age bone density, and corticosteroid use
46. Histomorphometric profile, pathophysiology, and reversibility of glucocorticoid-induced osteoporosis
47. Mean wall thickness and formation periods of trabecular bone packets in glucocortico-steroid-induced osteoporosis
48. Glucocorticosteroid and bone
49. Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study
50. The effect of cortisone on lamellar osteoblastic activity
51. Glucocorticoid-induced osteoporosis: Both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation
52. Hydrocortisone-induced inhibition of protein synthesis and uridine incorporation in isolated bone cells in vitro
53. Serum osteocalcin (bone gla-protein) and steroid osteoporosis in rheumatoid arthritis
54. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men
55. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects
56. The course of biochemical parameters of bone turnover during treatment with corticosteroids
57. Low serum osteocalcin levels in glucocorticoid-treated asthmatics
58. Relationship of glucocorticoid dosage to serum bone gla-protein concentration in patients with rheumatologic disorders
59. Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis
60. Effect of glucocorticoids on function of the parathyroid glands in man
61. Calcium and phosphorus homeostasis in man: Effect of corticosteroids
62. Osteopenia in patients with rheumatic diseases: Principles of diagnosis and therapy
63. Altered mineral metabolism in glucocorticoid induced osteopenia: Effect of 25-hydroxyvitamin D administration
64. Production, degradation and circulating levels of 1,25-dihydroxyvitamin D in health and chronic glucocorticoid excess
65. Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man
66. Intestinal calcium absorption in exogenous hypercortisolism: Role of 25-hydroxyvitamin D and corticosteroid dose
67. Effects of cortisone treatment on the active transport of calcium by the small intestine
68. Effects of 1,25-dihydroxycholecalciferol on intestinal calcium transport in cortisone-treated rats
69. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy
70. Corticosteroids and osteoporosis
71. Steroid osteoporosis
72. The assessment of the systemic effects of inhaled glucocorticosteroids - The effects of inhaled budesonide vs. oral prednisolone on calcium metabolism
73. Elevated 1,25-dihydroxyvitamin-D levels in patients with chronic obstructive pulmonary disease treated with prednisone
74. Calcium absorption in the rat in relation to excessive vitamin D and cortisone
75. Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man
76. Influence of low dose of sterol therapy on calcium absorption
77. Retention of orally administered 47-calcium in man under normal diseased conditions studies with a whole-body counter technique
78. 3 in patients on corticosteroid treatment and in patients with senile osteoporosis
79. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients
80. Vitamin D metabolites and parathyroid hormone in Cushing's syndrome: Relationship to calcium and phosphorus homeostasis
81. Unanticipated stimulatory action of glucocorticoids on epithelial calcium absorption. Effect of dexamethasone on rat distal colon
82. Effect of dexamethasone on electrolyte transport in the large intestine of the rat
83. The intestinal handling of calcium by the rat in vivo, as affected by cortisol. Effect of dietary calcium supplements
84. Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy
85. 3 in Children receiving glucocorticoids
86. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells
87. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects
88. Reversible gonadotrophin deficiency in male Cushing's disease
89. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells
90. Cortisol-induced suppression of plasma testosterone in normal adult males
91. Effect of glucocorticoids on plasma testosterone in men
92. Reduction of serum testosterone levels during chronic glucocorticoid therapy
93. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids
94. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving B-estradiol
95. Bone density determinants in elderly women: A twin study
96. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: A study of postmenopausal twins
97. Testosterone levels during systemic and inhaled corticosteroid therapy
98. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
99. Alcohol, cytokines, and estrogen in the control of bone remodeling
100. Alcohol-induced bone disease: Impact of ethanol on osteoblast proliferation
101. Exercises for female osteoporosis: A systematic review of randomized clinical trials
102. Relationship between exercise and bone mineral density amoung over 5,000 women aged 40 years and above
103. Cigarette smoking and bone mineral density in the elderly
104. Cigarette smoking, sex hormones and bone density in women
105. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects
106. Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women
107. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
108. Differential effects of endocrine dysfunction on the axial and appendicular skeleton
109. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporosis fractures
110. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparative study
111. Isolated skeletal involvement in Cushing's syndrome: Response to therapy
112. Quantitative microradiographic study of bone remodelling in Cushing's syndrome
113. Effect on bone growth of daily versus alternate day corticosteroid administration: An experimental study
114. Bone loss in adults receiving alternate day glucocorticoid therapy
115. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
116. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
117. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
118. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
119. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
120. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
121. The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach
122. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss
123. Intermittent cyclical etidronate therapy in the prevention of corticosteroid-induced osteoporosis
124. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis
125. The prevention of corticosteroid induced osteoporosis with intermittent cyclical etidronate
126. Increased bone density in patients on steroids with etidronate
127. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss
128. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
129. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial
130. Prevention of corticosteroid-induced with alendronate in sarcoid patients
131. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant cell arteritis
132. Prevention of bone loss with risedronate in glucocorticoid-treatment rheumatoid arthritis patients
133. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment
134. Cyclic etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: A double-blind, randomized placebo controlled study
135. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate
136. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
137. Effects of alendronate for two years and BMD and fractures in patients receiving glucocorticoids
138. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study
139. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
140. Intermittent etidronate and corticosteroid-induced osteoporosis
141. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
142. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis treated with and without steroids
143. Tamoxifen protects against steroid-induced bone loss
144. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
145. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis
146. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica
147. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol, and calcitonin
148. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?
149. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study
150. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma
151. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis
152. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis
153. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
154. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: A double-masked randomized study
155. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis
156. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial
157. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
158. Testosterone therapy in glucocorticoid-treated men
159. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate
160. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: A 3 year follow-up
161. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: A randomized, double-blind placebo controlled trial
162. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: A pilot study
163. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia
164. Effect of oral 1, 25-dihydroxy vitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases
165. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis
166. A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women
167. Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol
168. Possible prevention and treatment of steroid-induced osteoporosis